The healthcare technology company founded by UCSF researcher Jeffery Lotz, PhD, that leverages Magnetic Resonance Spectroscopy (“MRS”), artificial intelligence, and a proprietary biomarker to optimize clinical treatments for low back and neck pain, today announced the pricing of its initial public offering of 2,165,000 shares of its common stock and accompanying warrants to purchase up to 2,165,000 shares of common stock for a total of $9.4 Million as they launch their IPO.
